×

RNS Number : 3609Q

LoopUp Group PLC

05 June 2018

 

 

5 June 2018   LoopUp Group PLC   ("LoopUp" or the "Company")   Completion of Acquisition of MeetingZone Group   LoopUp Group PLC (LSE AIM: LOOP), the premium remote meetings company, is pleased to announce that following the re-admission of its Enlarged Share Capital to trading on AIM on 4 June 2018, it has successfully completed the acquisition of MeetingZone Group, a UK-headquartered conferencing services provider.   Terms used in this announcement shall have the meanings given to them in the Company's admission document dated 16 May 2018 unless otherwise specified. Steve Flavell, Co-CEO of LoopUp commented:   "Today marks a major milestone in LoopUp's development. This is a transformational step for the Company – MeetingZone enhances our already strong competitive position, adds significant scale to the business, amplifies the network effect of our offering, and brings a close and long-standing partnership with Cisco. We are excited to welcome MeetingZone into our newly-enlarged group. Together, we have an exciting opportunity to transform the way remote meetings take place and drive long-term growth and value for our shareholders."     For further information, please contact:   LoopUp Group PLC via FTI Steve Flavell, co-CEO       Panmure Gordon (UK) Limited +44 (0) 20 7886 2500 Dominic Morley / Alina Vaskina (Corporate Finance)   Erik Anderson (Corporate Broking)       Numis Securities Limited +44 (0) 20 7260 1000 Simon Willis / Jonny Abbott (Corporate Finance)   Tom Ballard (Corporate Broking)       FTI Consulting, LLP +44 (0) 20 3727 1000 Matt Dixon / Harry Staight / Jamille Smith           About LoopUp Group plc   LoopUp (LSE AIM: LOOP) is a premium remote meetings solution. Streamlined and intuitive, LoopUp is built for business users and delivers the quality, security and reliability required in the enterprise. One-click screen sharing and integration with tools business people use every day, like Outlook™, make it easy for LoopUp users to collaborate in real time. LoopUp's award-winning SaaS solution doesn't overwhelm users with features, and doesn't require training. Over 2,000 enterprises worldwide, including Travelex, Kia Motors America, Planet Hollywood, National Geographic, and Subaru trust LoopUp with their remote meetings.   The Group is headquartered in London, with offices in San Francisco, New York, Boston, Hong Kong, Barbados and Australia, and is listed on the AIM market of the London Stock Exchange (LOOP). For further information, please visit: www.loopup.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

ACQFKPDPKBKDBAK

Close

×

RNS Number : 2403Q

Netcall PLC

05 June 2018

 

RNS Reach

5 June 2018

NETCALL PLC

("Netcall", the "Company", or the "Group")

 

Contract Renewal

 

Netcall plc (AIM: NET), a leading provider of low-code and customer engagement software, is pleased to announce that its wholly owned subsidiary, MatsSoft Ltd, has secured a contract renewal with one of the UK's largest financial services institutions (the "Customer"). The four-year contract is worth a minimum of £3.7 million.

 

Since implementing MatsSoft's low-code platform ("MATS"), the Customer has developed a broad range of applications on the platform, supporting a significant number of operational processes.

 

The MATS platform drives innovation and digital transformation, from enterprise scale strategic services to niche applications that enhance the customer experience, lower and mitigate risk and reduce operating costs.

 

Henrik Bang, CEO of Netcall, commented: "We are delighted to continue our partnership with this important financial services institution. The contract win emphasises the value our platform brings as organisations transition into digital businesses. With MATS recognised as a market leading low-code platform, we are well positioned to benefit from the growing market opportunity."

 

For further enquiries, please contact:

 

Netcall plc	Tel. +44 (0) 330 333 6100
Henrik Bang, CEO James Ormondroyd, Group Finance Director
Alma PR	Tel. +44 (0) 20 8004 4218
Caroline Forde / Josh Royston / Robyn Fisher

 

About Netcall plc

Netcall is a UK company quoted on the AIM market of the London Stock Exchange. Netcall helps organisations transform their customer engagement activities and enable digital transformation faster and more efficiently, thereby improving customer experiences and operational efficiencies. Netcall's software product portfolio comprises Liberty, a customer engagement platform, incorporating omnichannel contact centre and workforce optimisation, and a leading low-code platform MATS.

 

Netcall has over 700 customers in both the private and public sectors. These include two-thirds of the NHS Acute Health Trusts, major telecoms operators such as BT and Vodafone, and leading organisations including Lloyds Banking Group, ITV and Nationwide Building Society.

 

For more information on Netcall visit www.netcall.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAUGUCWQUPRGCC

Close

×

Neville Registrars is delighted to welcome Rotala Plc as the newest addition to its list of client companies.

Rotala Plc provides a range of transport solutions for businesses, local authorities, the public and private individuals.

Further information can be found on the Company's website: http://www.rotalaplc.com/

Close

×

RNS Number : 4469P

Prospex Oil and Gas PLC

29 May 2018

 

Prospex Oil and Gas Plc / Index: AIM / Epic: PXOG / Sector: Oil and Gas

29 May 2018

Prospex Oil and Gas Plc ('Prospex' or the 'Company')
Production concession application submitted, onshore Italy

 

Prospex Oil and Gas Plc, the AIM quoted investment company, is pleased to announce that it has been advised by the operator Po Valley Energy Limited ('PVE') that a production concession application has been submitted to develop a new high return gas field in northern Italy (the 'Application').  The Application covers the 80.8km² Selva Gas-Field ('Selva'), which includes the Podere Maiar-1d appraisal/redevelopment well ('Podere Maiar' or 'the Well'), where strong flow rates from testing operations confirmed a significant commercial gas discovery in January 2018.  Prospex holds a 17% interest in Selva, which sits within the 331km² Podere Gallina Exploration Permit (the 'Podere Gallina'), which is located in the Po Valley region of Italy, a proven hydrocarbon province where over 5,000 wells have been drilled historically.

 

Podere Maiar was drilled in Q4 2017 into the Selva Gas-Field (previously operated by ENI), which historically produced 83Bcf of gas between 1960 and 1984. In December 2017 two gas-bearing reservoirs, C1 and C2, were encountered by the Well in the Medium-Upper Pliocene sands of the Porto Garibaldi formation with peak flow rates of 148,136 scm/day (5.2mmscf/d) on a 3/8 inch choke and 129,658 scm/day (4.6 mmscf/d) on a 3/8 inch choke achieved respectively in January 2018. 

 

Under the first phase of the development plan for the Well, PVE plan to install a fully automated gas plant at the existing Selva/Podere Maiar-1d well site at a cost of EUR2.4m and run a 1km long pipeline to connect with the nearby Italian National Grid connection. Based on dynamic reservoir studies, first phase production is targeted at a rate of up to 150,000 cubic metres (5.3 mmscf/day) a day from the successfully tested C1 and C2 reservoirs.  Accordingly, the formal Application, which has been submitted to the Italian Ministry, covers the installation of a fully automatic gas plant with capacity to produce 150,000 cubic metres (5.3mmscf/day) of gas a day. 

 

Crucially, significant further upside remains and in the second phase of the development plan (contingent on 3D seismic results), PVE intend to drill additional wells with a view to significantly increasing the size of the Selva natural gas resource.  Wells will be drilled in the field's highly prospective Selva East, Selva South Flank, and Riccardina prospects, all of which fall within the production concession application area.  3D seismic will be acquired (subject to JV approval) across these areas in the second half of 2018 and early 2019.

 

The Application will be considered for preliminary award at the next Italian Ministry Hydrocarbon Commission meeting, which is expected in July 2018. In the interim, PVE will prepare documentation for the requisite Environmental Impact Assessment so as to be able to commence the next stage of environmental approval pending preliminary award of the Application.

 

Commenting on the news Managing Director, Edward Dawson, said, "The submission of this production concession application marks a significant step forward in the commercialisation and recommencement of commercial gas production at the Selva Gas-Field in Italy.  Following the successful discovery of commercial gas at Podere Maiar earlier this year, PVE has designed a clear development plan from which to realise value in the near term whilst also proving up the potential of the wider licence area, with multiple prospects set to be advanced, each of which has the potential to significantly increase the size of the overall Selva Gas-Field. 

 

"Selva is set to be a high return natural gas field development and is undoubtedly a valuable asset within our multi-project investment company, which also includes the Bainet gas discovery in Romania, which is on course to commence production later this quarter, and the Tesorillo Project in southern Spain, which has gross unrisked Prospective Resources of up to 2 Tcf cubic feet of gas.  With multiple value triggers due in the coming months, we look forward to keeping shareholders updated on developments and believe 2018 is set to be a very exciting year for Prospex."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

* * ENDS * *

 

For further information visit www.prospexoilandgas.com or contact the following:

 

Edward Dawson	Prospex Oil and Gas Plc	Tel: +44 (0) 20 3766 0325
Rory Murphy Ritchie Balmer Jack Botros	Strand Hanson Limited	Tel: +44 (0) 20 7409 3494
Duncan Vasey	Peterhouse Corporate Finance	Tel: +44 (0) 20 7469 0932
Frank Buhagiar Charlotte Page	St Brides Partners Ltd	Tel: +44 (0) 20 7236 1177

 

Notes

Prospex Oil and Gas Plc is an AIM quoted investment company focussed on high impact onshore and shallow offshore European opportunities with short timelines to production. The Company's strategy is to acquire undervalued projects with multiple, tangible value trigger points that can be realised within 12 months of acquisition and then applying low cost re-evaluation techniques to identify and de-risk prospects. 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCEASSNASLPEEF

Close

×

RNS Number : 9074O

React Group PLC

22 May 2018

 

22 May 2018 

                                                              REACT Group plc

                                                  (the ''Company'' or ''React'')

Additional contract with major highways construction company

REACT is pleased to announce that it has signed an additional service contract with a major Highway's Construction Company for the provision of decontamination and deep cleaning services, for Picnic and Amenity sites and various service depots running from Dorset through Devon and Cornwall.  This is a 12 month rolling contract totalling £225,000. 

For further information please contact:  

REACT Group PLC

Gill Leates: Chairman                                                                                                   07799 662642

 

SPARK Advisory Partners Limited (NOMAD)                                                            0113 370 8974

Neil Baldwin

 

Whitman Howard Limited (Broker)

Nick Lovering                                                                                                                 0207 659 1224

 

Peterhouse Corporate Finance Limited (Broker)                                                      

Duncan Vasey / Martin Lampshire                                                                            0207 459 0930

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRALLFVFESIFFIT

Close

×

RNS Number : 6516O

Midatech Pharma PLC

21 May 2018

 

21 May 2018

Midatech Pharma PLC

("Midatech", "Company" or "Group")

 

Midatech commences equivalence study in exploratory phase of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly

 

–      Initial dosing administered in potentially pivotal phase for core near-to-market oncology asset

 

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, today announces that it has commenced initial dosing in the first in-human study of the Company's sustained release product Q-Octreotide (MTD201) for the treatment of carcinoid cancer and acromegaly, two rare and debilitating hormone-based tumours with high mortality and morbidity rates.

 

The clinical equivalence study is being conducted in 24 healthy subjects in a double-blind, randomised, parallel group protocol to evaluate the interchangeability between Q-Octreotide and the reference product, Sandostatin® LAR® ("SLAR"), following single dose administration. The aim is to establish equivalence of Q-Octreotide with SLAR, and to show that it can achieve safe and effective growth hormone levels in patients. The Company expects data for this study to be available in the second half of 2018 and intends to expand the study into a pivotal registration study, of similar design in up to 100 subjects, to complete in the first half of 2019.

 

The Company is seeking the same marketing product label indications as SLAR. Moreover, the Company plans to highlight the potential advantages of Q-Octreotide with prescribers and regulators. These advantages, made possible by Midatech's novel sustained release microsphere (Q-Sphera) technology, include: improved speed and simplicity of reconstitution along with fewer errors, a less painful injection with fewer blockages, minimal wastage with fewer repeat injections and errors, and improved economics.

 

Pending positive clinical data showing equivalence and completion of commercial scale manufacture requirements, the Company expects to file for marketing authorisation with the U.S. Food and Drug Administration (FDA) in 2020. The Company believes Q-Octreotide could capture up to 5% of the $2 billion annual market for SLAR1.

 

Midatech's CEO-designate, Dr Craig Cook, commented: "We are pleased to initiate this key study for one of our core programmes in oncology, MTD201, which also represents an important milestone for our sustained release Q-Sphera technology and its potential use in future products. Having resolved important manufacturing challenges and requirements, and incorporated invaluable regulatory authority feedback into the program design, we are confident that we have a robust study which will provide meaningful data on MTD201 in the second half of this year. Our pre-clinical data so far illustrates the interchangeability as well as numerous benefits of Q-Octreotide as a therapy for the debilitating and lethal diseases of carcinoid cancer and acromegaly versus the standard of care. We are working hard to bring this product to market to offer patients, physicians and payors an alternative choice for treating these diseases."

 

1 www.novartis.com; www.ipsen.com

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Craig Cook, CEO-designate

Nick Robbins-Cherry, CFO

Tel: +44 (0)1235 888 300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley / Emma Earl / Ryan McCarthy

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Nicholas Brown

Tel: +44 (0)20 3709 5700

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected]

 

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on the research and development of a pipeline of medicines for oncology and immunotherapy. Midatech's strategy is to internally develop oncology products, and to drive growth both organically and through strategic acquisitions. The Company's R&D activities are focused on three innovative platform technologies to deliver drugs at the "right time, right place": gold nanoparticles ("GNPs") to enable targeted delivery; Q-Sphera polymer microspheres to enable sustained release ("SR") delivery; and Nano Inclusion ("NI") to provide local delivery of therapeutics, initially to the brain. Midatech Pharma US is the Group's US commercial operation, with four cancer supportive care products and two further co-promoted products. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

About carcinoid cancer and acromegaly

Carcinoid cancer is a cancer of the neuroendocrine system in which tumours can grow in various regions of the body. Around 15,000 people are diagnosed with carcinoid tumours every year in the UK and the US.2 3 Acromegaly is an endocrine system disorder which develops when the pituitary gland produces excessive amounts of growth hormone. Around 4 people per million are diagnosed with acromegaly annually.4 Both conditions are rare and have high mortality and morbidity rates.

 

2 www.cancerresearchuk.org

3 www.cancer.net

4 www.pmj.bmj.com

 

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialize products for conditions using the nanoparticle and sustained release drug delivery platforms, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCLBLLLVEFFBBV

Close

×

RNS Number : 4127N

Microsaic Systems plc

09 May 2018

 

9 May 2018

Microsaic Systems plc

 

("Microsaic"or the "Company")

 

Agreement with Rightek Co., Ltd.

 

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that it has signed an agreement with Rightek Co., Ltd. ("Rightek") (the "Agreement").

 

The Agreement covers the distribution of Microsaic's 4500 MiD® mass spectrometry detector via Rightek's distribution network in Taiwan.

 

Glenn Tracey, CEO of Microsaic, commented, "This agreement with Rightek further consolidates our strategy to extend the sales of our unique compact, point of need technology into the Asia Pacific area.

 

Rightek combines expertise in understanding end-user applications, together with a proven track record of working with a wide range of specialised scientific instrumentation.

 

This agreement is in line with our strategy to partner with locally based and established channel partners, with expertise in selling innovative analytical instrumentation to progressive end-users in process and pharmaceutical markets."

 

Moses Shih, General Manager of Rightek, added "Rightek is committed to helping our customers achieve success, to solve their problems by finding suitable high-quality technologies to meet ever challenging demands. We believe that Microsaic's compact, point-of-need systems can improve the efficiencies by optimizing the process in chemical and pharma industries."

Enquiries:
Microsaic Systems plc Glenn Tracey, CEO Bevan Metcalf, FD	+44 (0) 1483 751577
N+1 Singer (Nominated Adviser & Broker) Shaun Dobson Liz Yong	+44 (0)20 7496 3000
IFC Advisory Ltd (Financial PR) Graham Herring Heather Armstrong Florence Chandler	+44 (0)20 3934 6630

 

 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

 

Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.  

 

 

About Rightek Co., Ltd

Established in December 2007, Rightek is headquartered in Wujin District, New Taipei City, and also has offices in Taichung and Kaohsiung. Rightek distributes a wide range of scientific equipment through its Analytical, Synthesis and Process Equipment divisions.

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGREASSPELEPEFF

Close

×

RNS Number : 5452N

EU Supply PLC

09 May 2018

 

RNS Reach

9 May 2018

EU Supply plc

("EU Supply", the "Company" or the "Group")

 

Contract Win

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that the Group has signed a contract with "Welthungerhilfe", a German private aid organisation. The contract is for delivery of CTMTM as SaaS and related services and is expected to generate, in aggregate, sales of €55k over a three year period.

 

 

FURTHER ENQUIRIES

EU Supply PLC Tel: 020 7127 4545 Thomas Beergrehn, CEO   Fredrik Wallmark, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, Ed Thomas

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for esourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 8,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAXKLFBVEFLBBK

Close

×

RNS Number : 2606N

Transense Technologies PLC

08 May 2018

 

Transense Technologies plc

("Transense" or the "Company")

New Translogik iTrack Contract Win in new Territory

 

Transense Technologies plc, the provider of sensor systems for the transportation and industrial markets, is pleased to announce that Translogik, its trading division providing tyre management solutions, has won a contract through its Ghanaian partner WATS (West African Tyre Services) to supply 16 iTrack II mining tyre monitoring systems for large haul trucks at SOMITA, a Nordgold mine in Burkina Faso.

These systems are to be supplied on a rental and service basis via WATS, which is a wholly owned subsidiary of Rana Motors & Metal Works Engineering Company Ltd. This method allows mining companies to benefit from the productivity gains and overhead savings provided by using the system without any of the associated capital cost while providing Translogik with a recurring revenue stream.

Vibi Chandra, Director, Sales & Services Director, OTR Tyres, WATS, said: "Having conducted extensive trials over the course of the last 18 months we have chosen iTrack because its combination of live alerts and extensive suite of data analytics is crucial to enhancing our offering as Tyre Service Providers. West Africa is a region with dozens of mines and hundreds of haul trucks and it is our intention to introduce our new enhanced service to our existing portfolio of mines as well as other mines across the region. We know these mines are very interested in the significant advantages we are now able to offer and we fully expect further advances and new contracts in the future."

 

Graham Storey, CEO of Transense, said: "We are very pleased to have added another mine in a new region to our growing list of iTrack users. WATS are a well established and highly regarded Tyre Service Provider in West Africa and with their depth of contacts we are hopeful of an accelerated rate of adoption as we move forward."

 

For further information, please visit www.transense.co.uk or contact:

 

Transense Technologies plc Graham Storey, Chief Executive	Tel: +44 1869 238 380
finnCap (Nomad and Broker) Ed Frisby, Giles Rolls (Corporate Finance) Abigail Wayne, Camille Gochez (Corporate Broking)	Tel: +44 20 7220 0500

  

Notes to editors:

About iTrack II

The iTrack II Mining system provides fast, accurate, reliable real-time data on the condition of the tyres, combined with live tracking of vehicle location and status. Our 24/7 Control Room monitors the  pressures and temperatures live, and this information can, for example, be used to ensure tyres do not exceed critical heat thresholds, detect incorrect load distributions, predict suspension failures, eliminate manual tyre pressure checks and much more. All of these benefits increase health and safety as well as reducing maintenance and downtime, which maximises the hours a truck is working (On-Road Truck Working Hours), which directly correlates to an increase in production.

Existing iTrack users have reported increases in tyre life of up to 30% and fuel savings of up to 3%. Savings of this magnitude provide a rapid return on investment with the iTrack system paying for itself in a matter of months and where the rental option is chosen the system will pay for itself from day one.

www.trans-logik.com/itrack-2/

 

About WATS

WATS is a leading provider of earthmover/off-the-road tyre management services to the mining industry. Their credentials are based on a proven ability to reduce the cost of earthmover tyre operation for major open-pit miners while maximising production and enhancing safety. Advanced engineering systems and innovative maintenance, analysis and reporting technologies combine to consistently reduce client tyre costs, typically by 20% or more. As an independent technical adviser and service provider to mining companies in West Africa WATS has established an impressive track record.

 

http://www.watsltd.com/

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTFKODQPBKDBPK

Close

×

RNS Number : 8009M

Nanoco Group PLC

02 May 2018

 

NANOCO GROUP PLC

("Nanoco" or the "Group")

 

Nanoco Group PLC launches new business, Nanoco 2D Materials Ltd

 

Nanoco 2D Materials Ltd raises seed funding and announces collaboration with The University of Manchester and Nobel Laureate, Professor Konstantin Novoselov

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and nano-materials, announces the launch of Nanoco 2D Materials Ltd "2D Materials", a wholly owned subsidiary focused on the development and commercialisation of a new generation of nano-materials.

Two dimensional nano-particles are a platform technology which are one or two atoms thick and a few nanometres wide and represent a burgeoning field of material science.  Currently there is no cost-effective way to produce these 2D materials on a commercial scale nor any reliable method to ensure consistent properties suitable for the wide range of potential electronics, industrial and other applications. 

For the past year Nanoco has been collaborating with Professor Novoselov, 2010 winner of the Nobel Prize for Physics for his work on graphene, with the goal to establish feasibility for these exciting new materials.  Based on the positive results seen to date, 2D Materials has been created to formalise the partnership between the two groups, ensure funding is in place and continue the development of the technology.

The £400,000 funding comes from The University of Manchester in the form of a 10-year convertible loan note which carries a 6.5% coupon.

Dr Nigel Pickett, CTO and co-founder of Nanoco, said:

"By combining Nanoco's expertise with the knowledge base from Professor Novoselov's lab we have been able to push the boundaries of material science to come up with a new generation of versatile 2D nano-particles and are now utilising Nanoco's 15 years of scale-up expertise on methods to produce them at commercial scale.  Potential commercial applications for these materials span across a wide range of sectors including novel catalysts, photo-detectors, photovoltaics, inverters and light emitting devices."

Professor Novoselov added:

"It is exciting to see how quickly 2D materials, beyond graphene, has accelerated from the early research stage to the technology we now have. Working with a very knowledgeable and dedicated Nanoco team continues to be a very refreshing experience. The ability of our combined teams to focus on particular technological and performance parameters is allowing the rapid development of these 2D Materials."

 Clive Rowland, CEO of the University's innovation company UMI3, commented:

"Part of the University's strategy for commercialising graphene and its sister 2D materials is to work with existing companies and entrepreneurs to help them set-up R&D centres and new companies close to the campus to create a technology innovation ecosystem here – Graphene City®. I'm delighted that we are working with Nanoco, which itself is a spin-out from the University. Its experience in the handling and scaling up of nanomaterials and access to its relevant facilities were key factors in us deciding to support this initiative."

About the convertible note:

The £400,000 funding comes from The University of Manchester in the form of a 10-year convertible loan note which carries a 6.5% coupon. Interest payments are accrued until conversion or repayment of the loan takes place.  The loan note is convertible into new shares of 2D Materials and any conversion event is dependent on an additional £1m of third party investment into 2D Materials or sale or flotation of 2D Materials.

 

 

For further information, please contact:

 

Nanoco	Tel: +44 (0) 161 6037900
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer
Caroline Watson, Investor Relations Manager	Tel: + 44 (0) 7799 897357
[email protected]
Peel Hunt	Tel: +44 (0) 20 7418 8900
Adrian Trimmings
George Sellar
MHP Communications	Tel: +44 (0) 20 3128 8788
Reg Hoare / Giles Robinson / Pete Lambie [email protected]

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-technology to create a brighter, more sustainable future. Based on breakthrough science, Nanoco's proprietary manufacturing process enables the large-scale production of its cadmium-free CFQD® quantum dots for multiple applications including LCD display, lighting, healthcare, nano-materials and solar.

 

Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company, Merck KGaA of Germany and Wah Hong Industrial Corporation of Taiwan.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition. 

 

About UMI3

The University of Manchester I3 Ltd (www.umi3.com) is The University of Manchester's agent for intellectual property commercialisation. UMI3 is wholly owned by the University which has over a 30 year history of IP commercialisation.

UMI3's role is to bring as much of the University's ground-breaking inventions and software, as is relevant, into the commercial world. This we do principally by attracting entrepreneurs, investors and corporate venture partners to our campus and Innovation Centre (www.umic.co.uk) and then, through engagement with our academic colleagues, licensing or spinning out companies.

Since 2004 over 4,000 invention disclosures have been received. UMI3 has set up 41 spin-out companies and 51 social enterprise spin-outs, staff start-ups and assisted student start-ups. Over 7,500 licences and assignments have been brokered and over £360M has been invested by 3rd party venture funders in University of Manchester spin-outs, a number of which have received national and regional enterprise awards. It currently has over 100 projects in its portfolio at various stages of development.

 

The University's IP enterprises have generated over £115M to the University through the sale of shares in spin-outs, licensing income and through IP grants and contracts activity.

For more information, please visit www.umip.com

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

UPDEASSFELDPEFF

Close